Cargando…

Macitentan: An important addition to the treatment of pulmonary arterial hypertension

Macitentan is an orphan drug for the treatment of pulmonary arterial hypertension (PAH). Endothelin-1 (ET-1) plays a critical role of pathophysiology of PAH. Macitentan, a new dual endothelin receptor antagonist, has reportedly improved prognosis of PAH patients by delaying the progression of diseas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khadka, Anjan, Singh Brashier, Dick B, Tejus, Anantharamu, Sharma, Ashok Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Molecules of the Millennium
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319253/ https://www.ncbi.nlm.nih.gov/pubmed/25709357 http://dx.doi.org/10.4103/0976-500X.149151

Ejemplares similares

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Lorcaserin: A novel antiobesity drug
por: Brashier, Dick B. S., et al.
Publicado: (2014)

Boceprevir: A new hope against hepatitis C virus
por: Brashier, Dick B. S., et al.
Publicado: (2012)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011)

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

An upcoming drug for onychomycosis: Tavaborole
por: Sharma, Neha, et al.
Publicado: (2015)

Sofosbuvir: A novel treatment option for chronic hepatitis C infection
por: Bhatia, Harmeet Kaur, et al.
Publicado: (2014)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia
por: Mazhar, Faizan, et al.
Publicado: (2016)

Ceftaroline fosamil: A novel anti-Methicillin-resistant Staphylococcus aureus cephalosporin
por: Girish, C., et al.
Publicado: (2011)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Asenapine, a new sublingual atypical antipsychotic
por: Balaraman, R, et al.
Publicado: (2010)

Belatacept: A worthy alternative to cyclosporine?
por: Melvin, George, et al.
Publicado: (2012)

Agomelatine: A novel melatonergic antidepressant
por: Manikandan, S
Publicado: (2010)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
por: Goel, Divya
Publicado: (2014)

Fospropofol
por: Mahajan, Bharti, et al.
Publicado: (2012)

Istaroxime: A rising star in acute heart failure
por: Aditya, Suruchi, et al.
Publicado: (2012)

Inhaled insulin: A “puff” than a “shot” before meals
por: Brashier, Dick B. S., et al.
Publicado: (2015)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model()
por: Temple, I.P., et al.
Publicado: (2014)

The Millennium Project: the positive health implications of improved environmental sustainability
por: Melnick, Don J, et al.
Publicado: (2005)

Disease Emergence and Health Transitions in the Last Millennium
por: Donaldson, Liam
Publicado: (2000)

Will Medicine Be Revolutionised by Genomics?
por: Harris, Rodney
Publicado: (2000)

God, Mammon and the Physician: Medicine in England before the College
por: Rawcliffe, Carole
Publicado: (2000)

Changing Concepts of Health and Disease during the 20th Century
por: Booth, Christopher C
Publicado: (2000)

Imaging in Medicine through the 20th Century
por: Du Boulay, George
Publicado: (2000)

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension
por: Kim, Kyung-Hee, et al.
Publicado: (2018)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_al8u92jtrg40j35hnh81a19929